Kooperativer Bibliotheksverbund

Berlin Brandenburg

and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Type of Medium
Language
Year
  • 1
    Article
    Article
    Language: German
    In: Wiener klinisches Magazin, 2010, Vol.13(6), pp.14-15
    Description: Mit der Entdeckung des Proteins TRAIL in der Pathogenese einzelner Krebserkrankungen scheint man dem Verständnis der Tumorentwicklung einen Schritt näher gekommen zu sein. TRAIL kann die Apoptose von Tumorzellen auslösen. Fehlt es, oder wird es inhibiert, so können sich maligne Zellen vermehren. Damit hat das Protein eine wichtige Rolle bei der Entwicklung von Krebs, wie z. B. Eierstock-und Prostatakrebs. Deren Tumorzellen entwickeln aber immer wieder Mechanismen, um der Wirkung von TRAIL zu entgehen. Da die Wirkweise des Proteins nicht bei jeder malignen Erkrankung gleich zu sein scheint, muss der Mechanismus entitätsspezifisch beobachtet werden. Die Arbeitsgruppe der Medizinischen Universität Wien unter Leitung von Univ.-Prof, Dr. Michael Krainer hat bei dieser Forschungsarbeit einen wesentlichen Beitrag geleistet und ist daher in internationalen Netzwerken beteiligt, um die notwendige breite Basis für die Forschung zu erreichen und nützen zu können. Im Zusammenhang von TRAIL mit dem Prostatakarzinom erhielt kürzlich die 26-jährige Mariam Anees, eine PhD Studentin der Arbeitsgruppe Urologische Tumoren an der Medizinischen Universität Wien, den Austrian Life Science Award (ALSA). Die erst vor knapp zwei Jahren aus Islamabad, Pakistan, nach Wien gekommene PhD-Studentin fand Anhaltspunkte für genauere Prognosen und innovative Therapien bei fortgeschrittenem Prostatakrebs und publizierte ihre Ergebnisse kürzlich in „Cancer”. Stellenwert und Auswirkungen auf mögliche Therapiekonzepte von TRAIL erklärte Krainer im Gespräch.
    Keywords: Medicine & Public Health ; Medicine/Public Health, General;
    ISSN: 1869-1757
    E-ISSN: 1613-7817
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Language: English
    In: Cancer Research, 04/15/2012, Vol.72(8 Supplement), pp.LB-201-LB-201
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Language: English
    In: Cancer, 15 March 2011, Vol.117(6), pp.1172-82
    Description: TRAIL (tumor necrosis factor related apoptosis-inducing ligand) is involved in tumor immune surveillance and, thus, may be a potential cancer therapy. TRAIL expression in the tumor microenvironment has been shown to impact cancer survival in multiple tumor types, including ovarian cancer. We studied TRAIL expression and outcomes in patients with prostate cancer. A tissue microarray (TMA) of 200 prostate cancer patients and benign prostate tissue controls was used to assess the epithelial and stromal protein expression of TRAIL, death receptors (DR4 and DR5), decoy receptors (DcR1 and DcR2), and the FLICE inhibitory protein (FLIP(L) ). We correlated these expression patterns with clinicopathological parameters and determined its impact on recurrence-free survival. Nearly all (99.5%) prostate cancer tissues examined displayed either decreased expression of pro-apoptotic TRAIL receptors, increased FLIP(L) expression, or both. We observed elevated death receptor, decoy receptor, FLIP(L) , and epithelial TRAIL expression in prostate cancer epithelium. TRAIL expression in the stromal tumor microenvironment surrounding the prostate cancer was markedly lower. Elevated TRAIL expression in the tumor microenvironment was also significantly associated with increased recurrence-free survival (P = .014), after controlling for other prognostic markers. In contrast, epithelial expression of TRAIL did not have an effect on overall survival. Expression of the components of the pro-apoptotic TRAIL pathway is altered in prostate cancer. Moreover, TRAIL expression in the tumor microenvironment may affect recurrence-free survival rate of prostate cancer patients. Consequently, these results may be useful in devising future therapeutic strategies targeting the TRAIL pathway in prostate cancer.
    Keywords: Carcinoma -- Metabolism ; Prostatic Neoplasms -- Metabolism ; Tnf-Related Apoptosis-Inducing Ligand -- Metabolism
    ISSN: 0008-543X
    E-ISSN: 10970142
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: PLoS ONE, 2015, Vol.10(8)
    Description: Objective C-reactive protein (CRP) has previously been shown to serve as a prognostic parameter in women with gynecologic malignancies. Due to the lack of valid prognostic markers for uterine leiomyosarcoma (ULMS) this study set out to investigate the value of pre-treatment CRP serum levels as prognostic parameter. Methods Data of women with ULMS were extracted from databases of three Austrian centres for gynaecologic oncology. Pre-treatment CRP serum levels were measured and correlated with clinico-pathological parameters. Univariate and multivariable survival analyses were performed. Results In total, 53 patients with ULMS were included into the analysis. Mean (SD) CRP serum level was 3.46 mg/dL (3.96). Solely, an association between pre-treatment CRP serum levels and tumor size ( p = 0.04) but no other clinic-pathologic parameter such as tumor stage ( p = 0.16), or histological grade ( p = 0.07), was observed. Univariate and multivariable survival analyses revealed that CRP serum levels ( HR 2 . 7 [1 . 1–7 . 2] , p = 0.037) and tumor stage ( HR 6 . 1 [1 . 9–19 . 5] , p = 0.002) were the only independent prognostic factors for overall survival (OS) in patients with ULMS. Patients with high pre-treatment CRP serum levels showed impaired OS compared to women with low levels (5-year-OS rates: 22.6% and 52.3%, p = 0.007). Conclusion High pre-treatment CRP serum levels were independently associated with impaired prognosis in women with ULMS and might serve as a prognostic parameter in these patients.
    Keywords: Research Article
    E-ISSN: 1932-6203
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Language: English
    In: Cancer Research, 04/15/2012, Vol.72(8 Supplement), pp.3997-3997
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Language: English
    In: Cancer Research, 04/15/2011, Vol.71(8 Supplement), pp.4777-4777
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Language: English
    In: Cancer Research, 04/15/2011, Vol.71(8 Supplement), pp.3661-3661
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Language: English
    In: Cancer, 01 March 2013, Vol.119(5), pp.946-954
    Description: BACKGROUND. Current prognostic information in ovarian cancer is based on tumor stage, tumor grade, and postoperative tumor size. Reliable molecular prognostic markers are scarce. In this article, the authors describe epigenetic events in a frequently deleted region on chromosome 8p22 that influence the expression of tumor suppressor candidate 3 (TUSC3), a putative tumor suppressor gene in ovarian cancer. METHODS. Messenger RNA expression and promoter hypermethylation of TUSC3 were studied in ovarian cancer cell lines and in tumor samples from 2 large, independent ovarian cancer cohorts using polymerase chain reaction-based methods. RESULTS. The results indicated that TUSC3 expression is decreased significantly because of promoter methylation in malignant ovarian tumors compared with benign controls. Almost 33% of ovarian cancer samples had detectable TUSC3 promoter methylation. Furthermore, methylation status of the TUSC3 promoter had a significant and independent influence on progression-free and overall survival. CONCLUSIONS. TUSC3 hypermethylation predicted progression-free and overall survival in ovarian cancer. The current observations suggested a role for N-glycosylating events in ovarian cancer pathogenesis in general and identified the epigenetic silencing of TUSC3 as a prognostic factor in this disease. Cancer 2013. [copy 2012 American Cancer Society. Tumor suppressor candidate 3 (TUSC3), a putative tumor suppressor gene, is frequently down-regulated in ovarian cancer. The epigenetic silencing of TUSC3 is correlated with poor progression-free and overall survival in patients with ovarian cancer.
    Keywords: Tusc3 ; Methylation ; Ovarian Cancer ; Glycosylation ; Progression‐Free Survival ; Overall Survival ; Biomarker.
    ISSN: 0008-543X
    E-ISSN: 1097-0142
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Language: English
    In: Cancer Research, 07/15/2016, Vol.76(14 Supplement), pp.2697-2697
    Description: Synthetic lethality describes an interdependent relationship between two genes, where the loss of either one alone can be compensated, while the simultaneous loss of both genes causes a non-viable phenotype. In recent years, first therapeutics based on this concept entered the clinic, most notably the PARP inhibitors for BRCA12-mutated cancers.
    Keywords: Lethality ; Poly(Adp-Ribose) Polymerase ; Breast Cancer ; Biochemistry;
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Language: English
    In: Cancer Research, 07/15/2016, Vol.76(14 Supplement), pp.2407-2407
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages